Answers are grounded in this paper and cite their sources.
Background: GBR 1302 is a HER2xCD3 bispecific antibody engineered to direct T-cells to HER2expressing tumor cells. This ongoing firstinhuman study (NCT02829372) in subjects with HER2positive cancers aims to evaluate the safety, tolerability, and preliminary efficacy of GBR 1302.
No takes yet. Share an insight, caveat, or question.
Wermke et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: